Pharmaceutical

Adaptimmune’s Tecelra gains accelerated approval for synovial sarcoma

The MAGE-A4-targeted genetically modified T cell therapy is indicated for the treatment of synovial sarcoma.

Aug 3, 2024 - 04:00
Adaptimmune’s Tecelra gains accelerated approval for synovial sarcoma
The MAGE-A4-targeted genetically modified T cell therapy is indicated for the treatment of synovial sarcoma.
Read the original article

Tags:

Previous Article

Vir Bio trims staff and pipeline to focus on Sanofi-licensed programmes

Next Article

Casgevy: Launch sequence and price analysis of the first marketed CRISPR therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

How using AI in clinical trials accelerates drug development

How using AI in clinical trials accelerates drug develo...

Jun 15, 2023

Biotech fund Curie.Bio augments reserves with $380m to boost startups  

Biotech fund Curie.Bio augments reserves with $380m to ...

Jun 28, 2024

Bayer teams up with lncRNA-focused NextRNA in $547m deal

Bayer teams up with lncRNA-focused NextRNA in $547m deal

Aug 29, 2024